Condition category
Not Applicable
Date applied
20/08/2018
Date assigned
29/10/2018
Last edited
25/09/2019
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting
Publication status
Protocol

Plain English Summary

Background and study aims
Randomised control trials (RCTs) are considered the gold standard when evaluating the efficacy and effectiveness of health care interventions. Unfortunately, a significant number of well-designed RCTs struggle with the recruitment of clinicians and patients, subsequentl leading to a failure to reach their target sample size. In the UK, 55% of NIHR (National Institute for Health Research) trials between 2002 and 2008 met recruitment targets, but 45% of all trials needed funding extensions to meet their recruitment target. Studies within a trial (SWATs) are used to investigate ways of improving the conduct of RCTs. This study is a SWAT, embedded in the WHiTE 8 COPAL trial (a trial of two antibiotic regimens for hip fracture patients) to evaluate whether two interventions; Enhanced Trainee Principal Investigator (TPI) Package and/or an Additional Post Recruitment Email effects patient recruitment rates to the COPAL trial. These interventions have not been formally tested before in a RCT or in a hypothetical setting. The results of this SWAT will be used to inform the design of future RCTs to increase the recruitment rates of patients to multicentre trials in orthopaedics. The data will also inform future decisions regarding how best to deliver TPI training and improve trainee satisfaction during his/her period in the role.

Who can participate?
Trial centres participating in the WHiTE 8 COPAL RCT

What does the study involve?
Centres involved in the WHiTE 8 COPAL trial will be randomly allocated to one of four groups. Group A will receive the enhanced TPI intervention, group B will receive the enhanced TPI and digital nudge intervention, group C will receive standard practice and group D will receive the digital nudge intervention only. Groups receiving the enhanced TPI intervention (A and C) will receive education via telephone training, peer support through texting and WhatsApp and digital information. Groups receiving the digital nudge intervention will receive emails each time a new participant joins the WHiTE 8 COPAL trial, which will encourage and thank them for recruiting participants to the trial.

What are the possible benefits and risks of participating?
The benefit in participating is to contribute to a study where positive results may be used to influence the methodology of future RCTs to improve patient recruitment. There are no known risks to participants taking part in this study.

Where is the study run from?
Trial and Statistics Department, University of York (as part of a PhD project) (UK)

When is the study starting and how long is it expected to run for?
October 2017 to March 2020

Who is funding the study?
This research is not directly funded, but it is embedded in a RCT which is industry funded by Heraeus Medical GmbH (Germany)

Who is the main contact?
Nickil Agni
nickil.agni@googlemail.com

Trial website

Contact information

Type

Public

Primary contact

Mr Nickil Agni

ORCID ID

http://orcid.org/0000-0001-6665-0477

Contact details

ARRC Building,York Trials Unit
Department of Health Sciences
University of York
Heslington
YO10 5DD
York
YO10 5DD
United Kingdom

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

Swat repository store - Swat 67

Study information

Scientific title

A factorial randomised controlled trial embedded within WHiTE 8 COPAL looking at the effect of an Enhanced Trainee Principal investigator package and additional digital nudge on recruitment rates.

Acronym

EnTraP

Study hypothesis

The use of an enhanced trainee principal investigator package and/or digital nudge will increase the recruitment rate to a randomised controlled trial

Ethics approval

The University of York Health Sciences Ethics Committee, 16/03/2018, Ethics Approval ID: HSRGC/2018/266/C

Study design

Interventional multi-centre 2x2 factorial randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Other

Patient information sheet

Not available in web format, please use contact details to request a participant information sheet

Condition

Recruitment to trials

Intervention

All centres recruiting to the WHiTE 8 randomised controlled trial will be included, with the exception of the recruitment centre that the Chief Investigator (CI) for this factorial trial is based at. There will be a minimum of 20 centres involved with the trial and any additional sites brought online will also be included in this embedded study. The interventions will run for 6 months in each recruitment centre. We anticipate 2-3 centres opening to recruitment per month, therefore, we anticipate that this trial will run for 16 months in total. The factorial design will allow for the evaluation of two interventions in one trial thus presents a more cost-effective option than running two separate trials.
There will be four groups created through randomisation:
Group A – Enhanced TPI (trained principal investigator) Intervention only
Group B – Enhanced TPI and Digital Nudge intervention
Group C – Standard practice
Group D – Digital Nudge Intervention only
All groups will receive automatic emails when they randomise a patient to the WHiTE 8 trial as outlined in standard practice. There will be no interference with Group C to identify TPIs if the centres allocated to this group are unable to recruit to this role.
The WHiTE centres will be randomised 1:1:1:1 by minimisation to one of the four groups to balance key baseline characteristics. Self-reported site feasibility questionnaires completed by the recruitment centres will be used as information for minimisation. Minimisation will be based on the following factors:
1. Cluster size (Number of intracapsular hip fractures presenting per year, cut at median <300 or 300)
2. High vs Low recruiting centres (<9 or >9 per month)
3. Co-Recruitment to WHiTE 5 (yes/no)
This randomisation will be done by a specialist computer software MinimPy.
The enhanced TPI intervention involves education, peer support and digital supplementary information. This can be broken down into the following:
1. Education - one-to-one telephone training by the WHiTE 8 research follow to the TPI, covering:
1.1. Background to the WHiTE 8 trial
1.2. TPI role and benefits of participating
1.3. How to effectively perform the TPI role
1.4. How to recruit and randomise to the WHiTE 8 trial
2. Peer support - support and advice through SMS/WhatsApp messaging, with follow-up emails and telephone calls if required for problems related to carrying out the role
3. Digital supplementary information - provision of the following supplementary material by email, including:
3.1. Induction agenda
3.2. TPI manual and new TPI checklist
3.3. Induction summary presentation
3.4. WHiTE 8 consent flow diagram and protocol
3.5. TPI contact information consent form
The Digital Nudge intervention will be an email from the WHiTE 8 Copal Research Fellow each time a health care professional randomises to the trial. Each email will include these nudges:
1. Personalisation (clinician is named)
2. Encouragement through praise to continue recruiting
3. Statement of appreciation for recruiting a patient to the WHiTE 8 COPAL trial
4. Digital nudge within 72 hours after recruitment
The aim will be to email the recruiter within 72 hours and where a clinician has recruited multiple patients in the period, only one email will be sent referring to the number recruited in the period.

Intervention type

Mixed

Phase

Drug names

Primary outcome measure

The total number of patients recruited in 6 months to the WHiTE 8 COPAL trial, which is routinely collected for the Oxford CTU on a monthly basis for all WHiTE trials. Data will be collated on an Excel spreadsheet for each trial centre on a monthly basis until 6 months in total.

Secondary outcome measures

1. Time taken to begin each intervention from centre activation, taken from Oxford CTU records at the time of interventions commencing at each trial centre
2. Feasibility of delivering both interventions, determined from a logbook of data collected by the CI at 6 months
3. Conversion rate to recruitment from the proportion of those screened to be eligible in each of the intervention groups, taken from Oxford CTU records on a monthly basis
4. Feedback on the trainee perspective of the TPI role via a survey completed by the TPI in the last 2 weeks of their role
5. Time needed to conduct the 1:1 educational training session for TPIs, determined from a logbook of data collected by the CI at 6 months
6. Required time and method of additional contact for peer support of the TPIs, determined from a logbook of data collected by the CI at 6 months

Overall trial start date

01/10/2017

Overall trial end date

01/03/2020

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

All hospitals running the WHiTE 8 COPAL RCT

Participant type

Health professional

Age group

Adult

Gender

Both

Target number of participants

A minimum of 20 trial centres

Participant exclusion criteria

Does not meet inclusion criteria

Recruitment start date

22/08/2018

Recruitment end date

01/01/2020

Locations

Countries of recruitment

United Kingdom

Trial participating centre

John Radcliffe Hospital
Oxford
OX3 9DU
United Kingdom

Trial participating centre

Leicester Royal Infirmary
Leicester
LE1 5WW
United Kingdom

Trial participating centre

Poole Hospital
Poole
BH15 2JB
United Kingdom

Trial participating centre

Queen Alexandra Hospital
Portsmouth
PO6 3LY
United Kingdom

Trial participating centre

Queen Elizabeth Hospital
Birmingham
B15 2TH
United Kingdom

Trial participating centre

Royal Berkshire Hospital
Reading
RG1 5AN
United Kingdom

Trial participating centre

Princess Royal Hospital
Haywards Heath
RH16 4EX
United Kingdom

Trial participating centre

Royal Victoria Infirmary
Newcastle Upon Tyne
NE1 4LP
United Kingdom

Trial participating centre

Southmead Hospital
Bristol
BS10 5NB
United Kingdom

Trial participating centre

University Hospital Coventry
Coventry
CV2 2DX
United Kingdom

Trial participating centre

Queens Medical Centre
Nottingham
NG7 2UH
United Kingdom

Trial participating centre

University Hospital Wales
Cardiff
CF64 2XX
United Kingdom

Sponsor information

Organisation

University of York

Sponsor details

ARRC Building
York Trials Unit
Department of Health Sciences
Heslington
York
YO10 5DD
United Kingdom

Sponsor type

University/education

Website

Funders

Funder type

Other

Funder name

investigator initiated and funded

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

The aim is to publish the results of the study in a peer reviewed journal and present at conferences to the wider orthopaedic community. The study will also form as part of a PhD thesis chapter

IPD sharing statement:
The datasets generated during and/or analysed during the current study are not expected to be made available as all data analysed will be available in the final peer publication and there will be no benefit to accessing raw data.

Intention to publish date

01/04/2020

Participant level data

Not expected to be available

Basic results (scientific)

Publication list

2019 protocol in https://www.ncbi.nlm.nih.gov/pubmed/31543957 (added 25/09/2019)

Publication citations

Additional files

Editorial Notes

25/09/2019: Publication reference added. 02/11/2018: Internal review.